Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93768ArticlesСтатьиResearch ArticleIzbytochnaya massa tela i infektsiya: problemy vybora antibakterial'nogo preparataИзбыточная масса тела и инфекция: проблемы выбора антибактериального препаратаDvoretskiyL. IДворецкийЛ. ИГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ15032013153VOL 15, NO3 (2013)ТОМ 15, №3 (2013)475028122021Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93768

Эпидемиологические исследования свидетельствуют о неуклонном росте числа людей с избыточной массой тела. В 2007–2008 гг. у 68% жителей США индекс массы тела (ИМТ) превышал 25, что означало наличие избытка массы или ожирения у каждого второго из 3 американцев. По прогнозу Всемирной организации здравоохранения, к 2015 г. приблизительно 23 млрд взрослых будут иметь избыточную массу тела, величина которой у 700 млн среди них будет квалифицироваться как ожирение. Среди разных клинических аспектов ожирения, основными из которых являются метаболический синдром, ишемическая болезнь сердца, сахарный диабет (СД), некоторые виды злокачественных опухолей, апноэ во сне, наименее изученной проблемой, известной широкому кругу врачей, является ассоциация ожирения с инфекционной патологией. И, хотя в клинической практике была отмечена повышенная склонность к инфекциям у больных, страдающих ожирением, в настоящее время имеется явно недостаточно информации об эпидемиологии внебольничных и внутрибольничных инфекций при ожирении, механизмах повышенной склонности к инфекциям у лиц с избыточной массой тела, а также особенностях клинического течения инфекций и тактике антибактериальной терапии (АБТ) инфекций у пациентов с избыточной массой тела и ожирением.

Flegal K.M., Carroll M.D., Ogden C.L., Curtin L. R. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303: 235–4.Murugan A.T. Obesity and respiratory diseases. Chronic Respiratory Disease November 2008; 5 (4): 233–42.Falagas M.E., Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6: 438–46.Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007; 18: 313–25.Trayhurn P, Wood I. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem Soc Trans 2005; 33: 1078–81.Trayhurn P, Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–55.Halberg N, Wernstedt-Asterholm I, Scherer P.E. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008; 37: 753–68.Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes 2009; 117: 241–50.Juge-Aubry C.E., Henrichot E, Meier C.A. Adipose tissue: a regulator of inflammation. Best Prac Res Clin Endocrinol Metab 2005; 19: 547–66.Myers M.G., Cowley M.A., Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008; 70: 537–56.Morrison C.D. Leptin resistance and the response to positive energy balance. Physiol Behav 2008; 94: 660–3.Otero M, Lago R, Lago F et al. Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 2005; 579: 295–301.Karlsson E.A., Beck M.A. The burden of obesity on infectious disease. Exp Biol Med 2010; 235 (12): 1412–24.Lamas O, Marti A, Martinez J.A. Obesity and immunocompetence. Eur J Clin Nutr 2002; 56 (Suppl. 3): S42–45.Resta O, Foschino-Barbaro M.P., Legari G et al. Sleep - related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001; 25: 669–75.Murugan A.T. Obesity and respiratory diseases. Chronic Respiratory Disease 2008; 5 (4): 233–42.Guerra S, Sherrill D.L., Bobadilla A et al. The Relation of Body Mass Index to Asthma, Chronic Bronchitis, and Emphysema Chest 2002; 122 (4): 1256–63. http://thorax.bmj.com/content/63/7/649.full - aff-1McClean K.M., Kee F. http://thorax.bmj.com/content/ 63/7/ 649.full – aff-1 F., Young I.S., Elborn J.S. http://thorax.bmj.com/ content/63/7/649.full – aff-3 Obesity and the lung: 1 Epidemiology Thorax 2008; 63: 649–54.Beuther D.A. et al. Am J Respir Crit Care Med 2007; 175 (7): 661–6.Koenig S.M. Pulmonary complications of obesity. Am J Med Sci 2001; 321: 249–79.Beal M, Chesson A, Garcia T et al. A pilot study of quantitative aspiration in patients with symptoms of obstructive sleep apnea: comparison to a historic control group. Laryngoscope 2004; 114: 965–8.Rubinstein I. Nasal infl ammation in patients with obstructive sleep apnea. Laryngoscope 1995; 105: 175–7.Salerno F.G., Carpagnano E, Guido P et al. Airway inflammation in patients aff ected by obstructive sleep apnea syndrome. Respir Med 2004; 98: 25–8.Vaughan R.W., Conahan T.J. 3rd. Part I: cardiopulmonary consequences of morbid obesity. Life Sci 1980; 26: 2119–27.Vaughan R.W., Bauer S, Wise L. Volume and pH of gastric juice in obese patients. Anesthesiology 1975; 43: 686–9.Marik P, Varon J. The obese patient in the ICU. Chest 1998; 113: 492–8.Baik I, Curhan G.C., Rimm E.B. et al. A prospective study of age and lifestyle factors in relation to community acquired pneumonia in US men and women. Arch Intern Med 2000; 160: 3082–8.Jedrychowski W, Maugeri U, Flak E et al. Predisposition to acute respiratory infections among overweight preadolescent children: an epidemiologic study in Poland. Public Health 1998; 112: 189–95.Mancuso Р. Obesity and respiratory infections: Does excess adiposity weigh down host defense? Pulm Pharmacol Ther 2012 May 24 [Epub ahead of print].Geerlings S.E. et al. FEMS Immunol Med Microbiol 1999; 26 (3–4): 259–65.Falagas M.E., Karageorgopoulos D.E. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375: 248–51.Bauer L.A., Black D.J., Lill J.S. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 54: 621–5.Green B, Duffull S.B. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119–33.Bearden D.T., Rodvold K.A. Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clin Pharmacokinet 2000; 38: 415–26.Stein G.E., Schooley S.L., Peloquin C.A. et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427–32.Lamas O, Marti A, Martinez J.A. Obesity and immunocompetence. Eur J Clin Nutr 2002; 56 (Suppl. 3): S42–45.Mathison C.J. Skin and wound care challenges in the hospitalized morbidly obese patient. J Wound Ostomy Continence Nurs 2003; 30: 78–83.Bosma R.J., Krikken J.A., Homan van der Heide J.J. et al. Obesity and renal hemodynamics. Contrib Nephrol 2006; 151: 184–202.Pai M.P., Bearden D.T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27: 1081–91.Pearson T.C., Guthrie D.L., Simpson J et al. Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology. Br J Haematol 1995; 89: 748–56.Blouin R.A., Warren G.W. Pharmacokinetic considerations in obesity. J Pharm Sci 1999; 88: 1–7.Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич, 1998.Bauernfeind A. In vitro activity of diritrimycin in comparison with other new and established macrolides. J Antimicrob Chemother 1993; 31 (Suppl.): 39–49.Zarogoulidis P, Papanas N, Kioumis I et al. Macrolides:from in vitro anti–inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol Epub 2011; 22.Cazzola M, Blasi F, Ewig S. Antibiotics and the Lung. European Respiratory Momograph 2004; 9: 28.Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125 (Suppl.): 41–51.Equi A, Balfour-Lynn I.M., Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo–controlled crossover trial. Lancet 2002; 360: 978–84.Amsden G.W. Anti - inflammatory effects of macrolides – an underappreciated benefit in the treatment of community - acquired respiratory tract infections and chronic inflammatory pulmonary conditions. J Antimicrob Chemother 2005; 55 (1): 10–21.Panpanich R et al. Cochrane Database Syst Rev 2008; (1): CD00195.Murray J.J. et al. Otolaryngol Head Neck Surg 2005; 133 (2): 194–200.